Author’s note: I am grateful to President & CEO, Mr. Sujal Shah for granting me the call interview for this article.
Introduction
CymaBay Therapeutics (CBAY) is a small cap ($567M) clinical-stage biopharma developing innovative therapeutics for rare/orphan diseases and chronic liver diseases with high unmet medical needs. Seladelpar, the lead investigative drug candidate, is currently in Phase 3 and Phase 2b clinical trials for PBC and NASH, respectively. It is an oral, once-daily potent selective PPAR- δ agonist and a master regulator of bile acid, glucose and lipid homeostasis. Seladelpar and its metabolites